Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.
The US FDA has rejected Mallinckrodt Pharmaceuticals’ investigational candidate, stannsoporfin, intended for the treatment of newborns at risk of jaundice.
Charles River Laboratories is approaching its optimal capacity utilisation but says pricing will not improve until the rest of the preclinical CRO industry follows suit.
An uptick in the outsourcing of preclinical trials is expected as pharmaceutical companies look to restructure and cut costs, but that increase won't necessarily begin in 2013, according to an analyst.
Charles River Laboratories’ (CRL) preclinical division will continue to struggle in 2012 but the recent uptick in strategic partnership activity is a ray of hope according to a leading analyst.
Tax benefit from the sale of its US Phase I business helped CRO Charles Rivers Laboratories (CRL) to grow profits in the first quarter despite falling revenues and low demand.
Establishment of complex regulated preclinical studies in China is going to take a lot longer than expected, says CRL, with significant progress taking at least five years.
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
CRL has said the WuXi buy could add up to $100m (€78m) in additional annual revenue and spoken of clients’ enthusiasm for the deal as its attempts to shore up investor support.
Charles River Laboratories (CRL) has admitted that areas of overlap created by the WuXi acquisition will lead to a “refinement of certain operating units” but is yet to disclose details.
Charles River Laboratories (CRL) has bucked the CRO sector trend and reaffirmed its forecasts for 2009, citing an improved order book and better pricing as the reasons for its relative optimism.
